[Secondary infection of joint implants: diagnostic criteria, treatment and prevention]. / Infection secondaire de prothèse articulaire: critères du diagnostic, traitement et prévention.

Peroperative contamination is the most frequent cause of infection after arthroplasty. For other cases of infection subsequent to bacteremia or a neighboring focus, it would be more appropriate to use the term "secondary" infections rather than hematogeneous infections. Arguments favoring secondary infection include long symptom-free interval between prosthesis implantation and the infectious episode, a causal germ not generally responsible for peroperative infection, presence of a distant infectious focus, positive blood culture, and a positive bacteriological sample from the prosthesis level showing the same strain as grown from the distant focus or blood samples. Both acute and chronic infections are observed, leading to prosthesis dysfunction. History taking generally identifies a neglected acute but transient episode. Search for a bacteriological diagnosis must be completed before initiating an antibiotic regimen. If detected very early, washing with open synovectomy and resection of suspicious tissue should be attempted in order to maintain the implant if possible. Local antibiotics have proven efficacy. Beyond a certain delay, treatment for chronic infection usually requires removing the prosthesis, cleaning the bone interface, and new arthroplasty delayed or not. Search for the portal must be undertaken early in order to initiate appropriate local treatment. The causal event may be any invasive procedure, with or without material implantation. The risk-benefit ratio for antibiotic prophylaxis remains to be determined.

Treatment of bone and joint infection with teicoplanin: a retrospective analysis of 50 cases.

The effectiveness and safety of teicoplanin, 400 mg/day, in combination with other antibiotics in the treatment of bone and joint infections was examined in a retrospective review of 50 cases (most commonly sepsis, osteitis and septic arthritis) treated at one hospital between 1988 and 1994. Previous antibiotic treatment had failed in 36 cases. Patients received teicoplanin and 1-3 concurrent antibiotics for 4-141 days; 35 patients then received further antibiotics. Clinical success was recorded in 46 cases, with two failures and two non-evaluable outcomes. Bacteriological eradication was achieved in 43 cases. There was one recurrence at 8 months, which was successfully treated with teicoplanin. Five patients showed adverse reactions, but discontinuation of teicoplanin treatment was not necessary.

Treatment of 112 bone and joint infections with teicoplanin.

Teicoplanin was used in three hospitals over 6 years in 112 cases of bone or joint infection and the results were reviewed retrospectively. Teicoplanin was used at a dose of 400 mg/day, after a 3-day loading regimen, in combination with other agents, usually netilmicin at the beginning of the treatment. Most infections were chronic (mean duration = 20.9 months) and had failed previous antibiotic or surgical treatment. Gram-positive organisms were isolated in 120/137 identified strains (64 methicillin-resistant Staphylococcus aureus or coagulase négative Staphylococci) and all were susceptible to teicoplanin except one (intermediate for NCCLS norms). Median of follow-up was 17.3 months. The final outcome was clinical cure in 89/98 evaluable cases (91%). There were one improvement, four failures and four recurrences. Adverse events occurred in 11 patients (10%) but did not require any change in treatment. Despite the limitations of a retrospective study, teicoplanin appeared to be effective, well tolerated and easy to use with only one daily injection.RéSUMé: Une étude rétrospective, non comparative, de l'utilisation de la teicoplanine sur 112 cas d'infection ostéo-articulaire pendant 6 ans dans trois hopitaux Français est rapportée. La teicoplanine a été utilisée à la dose de 400 mg/j, après une dose de charge de 3 jours, en association avec d'autres antibiotiques (le plus souvent la netilmycine en début de traitement). Ces infections étaient chroniques (durée d'évolution moyenne de 20,9 mois) et avaient déjà fait l'objet de traitements antérieurs médicaux ou chirurgicaux. Cent vingt cocci gram positif étaient retrouvés sur les 137 souches isolées (64Staphylococus Aureus ou Epidermidis résistant à la methicillin) et tous sauf une (intermédiaire selon les normes NCCLS) étaient sensibles à la teicoplanine. Après une durée de suivi moyenne à 17,3 mois, 89 des 98 cas evaluables (91 %) étaient considérés comme guéris. On retrouvait également 1 amélioration, 4 échecs et 4 récurrences. Un effet secondaire a été noté chez 11 patients (10 %) mais n'a jamais necessité un changement de traitement témoignant ainsi de la bonne tolérance observée avec cette molécule facile à utiliser gràce à une seule injection par jour.

99Tcm-HMPAO-labelled leucocyte scintigraphy in suspected chronic osteomyelitis related to an orthopaedic device: clinical usefulness.

Thirty-five patients with suspected chronic osteomyelitis related to an orthopaedic device had 50 99Tcm-HMPAO-labelled leucocyte scans (LS). The scan appearances were compared with the bacteriological or clinical results and gave a sensitivity and specificity of HMPAO-LS of 83 and 100%, respectively. Bacteriological examination is often inaccurate in the diagnosis of osteomyelitis and therefore we assessed the clinical utility of HMPAO-LS. When the clinical, biological and radiological data were clearly suggestive of osteomyelitis (16/50) LS was unhelpful or even misleading when falsely negative (3/16). When the clinical, biological and radiological data were poorly suggestive of osteomyelitis (20/50) or conflicting (14/50) LS was misleading in only one patient (false negative). It is concluded that HMPAO-LS should only be performed to assist in the diagnosis of chronic osteomyelitis when there is no preexisting strong suspicion based on clinical, biological and radiological signs.

Antibiotic-impregnated plaster of Paris beads. Trials with teicoplanin.

Teicoplanin-impregnated plaster of Paris beads were made and in vitro release properties were studied. Teicoplanin was released in an initial massive dose, with a rapid decline during the first three days, followed by a slowly declining prolonged release up to 30 days. The release tested by diffusion in gelose and high-performance liquid chromatography was found to be 21.4% and 28.2%, respectively, of the amount theoretically present in the beads. Plaster of Paris is a resorbable, nontoxic biomaterial that has already been used to fill dead spaces in bone and deliver antibiotics in the treatment of chronic osteomyelitis. The addition of teicoplanin, a new antistaphylococcal agent with low known bacterial resistance, is a promising alternative. Follow-up tests in vivo, simulating local conditions of the osteomyelitic bone, are necessary to prove efficacy.